Validation of the CIBMTR scoring system in predicting early relapse of multiple myeloma after autologous hematopoietic cell transplant

Bone Marrow Transplant. 2023 Sep;58(9):1057-1058. doi: 10.1038/s41409-023-02024-1. Epub 2023 Jun 23.

Authors

Hussein Awada¹, Ali Hajj Ali², Faiz Anwer², Craig Sauter², Louis Williams², Jack Khouri²

Affiliations

¹ Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. awadah3@ccf.org.
² Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.

PMID: 37353570
DOI: 10.1038/s41409-023-02024-1

No abstract available

Publication types

Letter

MeSH terms

Chronic Disease
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma* / therapy
Neoplasm Recurrence, Local
Prognosis
Transplantation, Autologous